FDA Brief

Warning letters Drugs

FDA warning letter to

Zhejiang Easyclean Daily Chemical Co., Ltd

High riskIssued May 14, 2025Posted Jun 3, 2025Center for Drug Evaluation and Research (CDER)

FDA warned Zhejiang Easyclean Daily Chemical that its OTC drugs lacked required testing and manufacturing controls.

What happened

FDA reviewed records the company submitted after FDA's March 11, 2024 request for records and later correspondence; there was no inspection. The records showed no finished-product testing of active ingredient identity or strength before release, inadequate stability data and expiration dates, incomplete batch records, and no process validation for OTC drugs shipped to the U.S. market.

What FDA found

  1. Did not test each finished drug batch for identity and strength of active ingredients before release.

    21 CFR 211.165(a)
  2. Failed to establish an adequate stability program; it had only three months of accelerated data, no long-term data, and no testing of the active ingredient to support expiration dates.

    21 CFR 211.166(a)
  3. Batch production and control records lacked formulation, equipment identity, step durations, and names of people performing steps.

    21 CFR 211.188
  4. Had no written production and process control procedures and had performed no validation of its drug manufacturing processes.

    21 CFR 211.100(a)

What FDA wants

FDA tells the company to respond in writing within 15 working days with corrective action plans, finished-product testing plans, a stability program, complete batch records, and validation plans; it also recommends a qualified CGMP consultant.

Who should pay attention

  • U.S. distributors and retailers selling imported OTC drugs
  • brands using this contract manufacturer for private-label drugs
  • quality teams auditing overseas OTC drug suppliers

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk